Medpedia.net

Ambrisentan therapy in pulmonary hypertension: oedema is the most common side effect leading to cessation of therapy

Ambrisentan ( US: Letairis; EU: Volibris ) is an oral selective endothelin receptor antagonist licensed for use in pulmonary arterial... ... read

First-line combination of Ambrisentan and Tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension

Data of the first phase IIIb/IV study, AMBITION, were presented at the ERS International Congress 2014. The study has investigated... ... read

Pulmonary arterial hypertension: FDA has approved Ambrisentan

The FDA ( Food and Drug Administration ) has approved Letairis ( Ambrisentan ) for the treatment of pulmonary arterial... ... read

MedTV

MedVideo

Specialty ( English version )

Specialità ( Italian version )

Cardiologia
- News
- Farmaci
- Focus
Dermatologia
- News
- Farmaci
- Focus
Diabetologia
- News
- Farmaci
- Focus
Ematologia
- News
- Farmaci
- Focus
Emergenze
- News
- Farmaci
- Pronto Soccorso
Endocrinologia
- News
- Farmaci
- Focus
Farmacologia
- Farmaci
- Vaccini
- Farmacovigilanza
Gastroenterologia
- News
- Farmaci
- Focus
Ginecologia
- News
- Farmaci
- Focus
Infettivologia
- News
- Farmaci
- Focus
Metabolismo
- News
- Farmaci
- Focus
Nefrologia
- News
- Farmaci
- Focus
Neurologia
- News
- Farmaci
- Focus
Oftalmologia
- News
- Farmaci
- Focus
Oncologia
- News
- Farmaci
- Focus
Pneumologia
- News
- Farmaci
- Focus
Pediatria
- News
- Farmaci
- ADHD
Psichiatria
- News
- Farmaci
- Focus
Reumatologia
- News
- Farmaci
- Focus
Urologia
- News
- Farmaci
- Focus